Company intelligence / Profile preview

Wuxi Sinotide New Drug Discovery Institutes

Wuxi, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Wuxi Sinotide New Drug Discovery Institutes is a biotechnology company specializing in the discovery and development of innovative peptide-based therapeutics. The company leverages a proprietary peptide discovery platform to design high-affinity and stable peptide candidates, including bicyclic peptides and peptide-drug conjugates. Their primary research focus is on metabolic diseases, such as obesity and type 2 diabetes, as well as oncology. Sinotide operates as both a drug discovery entity and a provider of specialized research services to the global pharmaceutical industry.

Therapeutic areas: OncologyMetabolic DisordersEndocrinology
Modalities: PeptidesBicyclic peptidesPeptide-drug conjugateSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Wuxi Sinotide New Drug Discovery Institutes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuxi Sinotide New Drug Discovery Institutes.

Explore the full profile